Tharimmune Performance

THARDelisted Stock   4.95  0.21  4.43%   
Tharimmune holds a performance score of 17 on a scale of zero to a hundred. The entity has a beta of 2.17, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Tharimmune will likely underperform. Use Tharimmune value at risk, and the relationship between the jensen alpha and skewness , to analyze future returns on Tharimmune.

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Tharimmune are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Tharimmune reported solid returns over the last few months and may actually be approaching a breakup point. ...more
1
Insider Trading
12/03/2025
2
Bravado on railway tracks Internet questions irresponsible trait of Thar-owners, Not a car...
12/18/2025
3
Tharimmune files for mixed shelf of up to 2.0 bln - SEC filing - MarketScreener
01/09/2026
4
Tharimmune Addresses Nasdaq Board Independence Compliance Notice - TipRanks
01/15/2026
5
Tharimmune, Inc. Announces Pricing of 55 Million Underwritten Registered Offering
01/20/2026
6
Tharimmune, Inc. Announces Closing of 55 Million Underwritten Registered Direct Offering
01/22/2026
7
Tharimmune Gains Approval To Run Super Validator On Canton Network - Nasdaq
01/29/2026
8
Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
02/17/2026
  

Tharimmune Relative Risk vs. Return Landscape

If you would invest  245.00  in Tharimmune on November 21, 2025 and sell it today you would earn a total of  250.00  from holding Tharimmune or generate 102.04% return on investment over 90 days. Tharimmune is currently generating 1.3858% in daily expected returns and assumes 6.1488% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Tharimmune, and 73% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Tharimmune is expected to generate 8.23 times more return on investment than the market. However, the company is 8.23 times more volatile than its market benchmark. It trades about 0.23 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.17 per unit of risk.

Tharimmune Target Price Odds to finish over Current Price

The tendency of Tharimmune Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 4.95 90 days 4.95 
about 1.82
Based on a normal probability distribution, the odds of Tharimmune to move above the current price in 90 days from now is about 1.82 (This Tharimmune probability density function shows the probability of Tharimmune Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.17 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Tharimmune will likely underperform. Additionally Tharimmune has an alpha of 0.7588, implying that it can generate a 0.76 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Tharimmune Price Density   
       Price  

Predictive Modules for Tharimmune

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tharimmune. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.255.0211.17
Details
Intrinsic
Valuation
LowRealHigh
0.193.759.90
Details
Naive
Forecast
LowNextHigh
0.094.5310.68
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-1.434.4610.35
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Tharimmune. Your research has to be compared to or analyzed against Tharimmune's peers to derive any actionable benefits. When done correctly, Tharimmune's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Tharimmune.

Tharimmune Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Tharimmune is not an exception. The market had few large corrections towards the Tharimmune's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Tharimmune, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Tharimmune within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.76
β
Beta against Dow Jones2.17
σ
Overall volatility
0.86
Ir
Information ratio 0.13

Tharimmune Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tharimmune for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tharimmune can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Tharimmune is now traded under the symbol CNTN. Please update your portfolios or report it if you believe this is an error. Report It!
Tharimmune is way too risky over 90 days horizon
Tharimmune appears to be risky and price may revert if volatility continues
Tharimmune has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (12.2 M) with profit before overhead, payroll, taxes, and interest of 0.
Tharimmune generates negative cash flow from operations
About 23.0% of the company outstanding shares are owned by corporate insiders
Latest headline from prnewswire.com: Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy

Tharimmune Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tharimmune Stock often depends not only on the future outlook of the current and potential Tharimmune's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tharimmune's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding1.3 M
Cash And Short Term Investments3.6 M

Tharimmune Fundamentals Growth

Tharimmune Stock prices reflect investors' perceptions of the future prospects and financial health of Tharimmune, and Tharimmune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tharimmune Stock performance.

About Tharimmune Performance

Assessing Tharimmune's fundamental ratios provides investors with valuable insights into Tharimmune's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tharimmune is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.

Things to note about Tharimmune performance evaluation

Checking the ongoing alerts about Tharimmune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tharimmune help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Tharimmune is now traded under the symbol CNTN. Please update your portfolios or report it if you believe this is an error. Report It!
Tharimmune is way too risky over 90 days horizon
Tharimmune appears to be risky and price may revert if volatility continues
Tharimmune has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (12.2 M) with profit before overhead, payroll, taxes, and interest of 0.
Tharimmune generates negative cash flow from operations
About 23.0% of the company outstanding shares are owned by corporate insiders
Latest headline from prnewswire.com: Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
Evaluating Tharimmune's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Tharimmune's stock performance include:
  • Analyzing Tharimmune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tharimmune's stock is overvalued or undervalued compared to its peers.
  • Examining Tharimmune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Tharimmune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tharimmune's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Tharimmune's stock. These opinions can provide insight into Tharimmune's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Tharimmune's stock performance is not an exact science, and many factors can impact Tharimmune's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tharimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Tharimmune Stock

If you are still planning to invest in Tharimmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tharimmune's history and understand the potential risks before investing.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
CEOs Directory
Screen CEOs from public companies around the world
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets